Overview
This is a study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HRS-6209 combined with letrozole in breast cancer patients, and preliminarily observe its anti-tumor efficacy.
Eligibility
Inclusion Criteria:
- Women aged 18-75 years.
- ECOG performance status 0-1.
- Menopausal status.
- Evidence of radiographic disease progression during or after the last systemic anti-tumor therapy prior to the first study drug administration.
- At baseline, there must be at least one measurable, extracranial lesion that meets RECIST v1.1 criteria.
- Expected survival > 3 months.
- Women of childbearing potential must agree to use highly effective contraceptive measures during the study treatment and for 6 months after the end of treatment. Women of childbearing potential must have a negative serum HCG test within 7 days prior to study enrollment and must not be breastfeeding.
- Voluntarily agree to participate in this clinical trial, willing and able to comply with the study visits and procedures, understand the study procedures, and have signed the informed consent form.
Exclusion Criteria:
- Symptomatic visceral metastasis and other conditions, and the researcher judged that endocrine therapy was not suitable for use.
- History of clinically serious cardiovascular disease.
- The ECG examination was abnormal.
- Patients with clinically significant endometrial abnormalities, including but not limited to endometrial hyperplasia and dysfunctional uterine bleeding.
- The subjects were in acute infection or active tuberculosis and needed drug treatment.
- The patients received surgery, chemotherapy, immunotherapy and macromolecular targeted therapy within 4 weeks before the first medication.
- Pregnant and lactating women, or intending to become pregnant during the study.
- There was a clear history of neurological or mental disorders and the subjects had a history of psychotropic drug abuse or drug abuse.
- In the course of this study, it is expected to receive other anti-tumor treatments or drugs.